Advice
following a full submission:
rivaroxaban (Xarelto®) is accepted for use within NHS Scotland.
Indication under review: treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults.
Rivaroxaban was non-inferior to a regimen including a low molecular weight heparin and a vitamin K antagonist for the treatment of PE and the prevention of recurrence of DVT or PE. Duration of treatment was 3, 6 or 12 months at the discretion of the treating physician.
Experience with rivaroxaban in this indication for more than 12 months is limited therefore the cost-effectiveness of indefinite treatment has not been demonstrated.
Download detailed advice147KB (PDF)
Medicine details
- Medicine name:
- rivaroxaban (Xarelto)
- SMC ID:
- 852/13
- Indication:
- Treatment of pulmonary embolism (PE), and prevention of recurrent deep vein thrombosis (DVT) and PE in adults.
- Pharmaceutical company
- Bayer plc/Bayer Schering Pharma
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 March 2013